Autor(es):
Duarte,Fernando Barroso ; Santos,Talyta Ellen de Jesus dos ; Barbosa,Maritza Cavalcante ; Kaufman,Jacques ; Vasconcelos,João Paulo de ; Lemes,Romélia Pinheiro Gonçalves ; Rocha,Francisco Dário ; Coutinho,Diego Ferreira ; Zalcberg,Ilana ; Vasconcelos,Paulo Roberto Leitão de
Data: 2016
Origem: Oasisbr
Assunto(s): Myelodysplastic Syndrome; Hematopoietic Stem Cell Transplantation; Prognosis
Descrição
ABSTRACT The hematopoietic stem cell transplantation (HSCT) is the only curative alternative for Myelodysplastic Syndrome (MDS), but many patients are not eligible for this treatment, as there are several limiting factors, especially in the case of patients with low-risk MDS. The aim of this study is to discuss the factors that can guide the decision-making on referring or not a patient to HSCT. Three cases of MDS, two of which were submitted to HSCT are presented. We intend to report the difficulties in referring patients with MDS to transplant and the prognostic factors that contribute to define eligibility.